A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 14194 participants.

Also called NCT05754957

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 14,194 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05754957
  • EU CT 2022-501418-69-00
Other papers using this trial's data
  • Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event The New England journal of medicine, 2026-10-22 DOI, PubMed 42670965

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, North Macedonia, Philippines, Poland, Portugal, Romania, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Türkiye, United Kingdom, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05754957. Randomized; quadruple masking; primary purpose treatment. Start 2023-04-07 (actual); primary completion 2026-02-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Acronym
LIBREXIA-ACS
Condition
Acute Coronary Syndrome
Intervention (Drug)
Milvexian
Intervention (Other)
Placebo
Lead sponsor
Janssen Research & Development, LLC (class: industry)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct05754957
Content hash
314cb5e5ac5fac04cdd8c9a0d63f7a9482af4a2768508b32826a7df2fff4dbcf